4 results
Approved WMOCompleted
To evaluate the long-term safety and tolerability of Dimebon in AD patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION Study (DIM14) (hereafter referred to as *CONNECTION*).
Approved WMOCompleted
To determine the safety and efficacy of Dimebon in patients with mild to moderate Huntington Disease
Approved WMOCompleted
Primary Objective1. The main objective of this study is to demonstrate that OM/AML/HCTZ triple combinations are more efficacious in lowering SeDBP than corresponding dual combinations of OM/AML after 10 weeks of double blind treatment.Secondary…
Approved WMOCompleted
To determine the safety and efficacy of Dimebon in patients with mild-to-moderate Huntington Disease